JZP-110: Phase III started

Jazz began the double-blind, placebo-controlled, North American Phase III Study 14-003 to evaluate 37.5, 75, 150 and 300 mg oral JZP-110 once daily for 12 weeks in about 440 patients. Patients may be ...